OrganaBio announced that it has acquired all of Excellos’ operating assets, establishing a bicoastal cell therapy contract testing, development, and manufacturing organization.
Under the transaction, newly formed subsidiary Excellos Labs will oversee San Diego operations moving forward. OrganaBio said the acquisition expands its geographic footprint and combines complementary capabilities across manufacturing, PBMC isolation, cryopreservation, and cell processing services for cell therapy developers.
The company said the combined platform now spans multiple facilities throughout the United States. OrganaBio’s Miami headquarters serves as the East Coast anchor with leukapheresis, birth tissue and cord blood sourcing, ISO 7 cGMP cleanrooms, process development, quality control testing, PBMC isolation, and cryopreservation capabilities. On the West Coast, the company operates processing and cryopreservation labs in San Francisco and Irvine, California, and has added Excellos’ San Diego facility, featuring five ISO 7 cGMP cleanroom suites supporting autologous and allogeneic cell therapy manufacturing.
OrganaBio retained the core Excellos team as part of the acquisition and said existing customer programs will continue without interruption during the integration process. The company noted that the combined organization is designed to help address supply chain and operational challenges faced by cell therapy developers by providing manufacturing redundancy and geographic diversification under a unified quality framework.
The combined customer base includes many of the top 20 global pharmaceutical companies along with public and private biotechnology developers. The platform supports therapeutic programs focused primarily on cancer and autoimmune indications across both clinical and commercial-stage autologous and allogeneic cell therapies.
OrganaBio said full integration of the businesses is expected over the next 12 months, with priorities centered on maintaining operational continuity, expanding services, improving operational speed and quality, and supporting future growth across the combined platform.
Financial terms of the acquisition were not disclosed.
KEY QUOTES:
“Cell therapy developers and the patients waiting on their programs need a manufacturing partner that can match the pace and quality of their work. Combining OrganaBio’s and Excellos’ infrastructure and teams lets us do that more reliably than either company could alone. Our priority in the coming months is operational continuity for every customer of both companies, with broader capabilities layered in as integration progresses.”
Justin Irizarry, CEO, OrganaBio
“This acquisition is the best of both worlds, ensuring continuity for Excellos’ customers as we move into our next phase while adding critical redundancy, expanded geographical reach, and access to additional services and material including cord blood.”
Tom VanCott, CEO, Excellos
